Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data

Jun Yin, Xavier Paoletti, Daniel J. Sargent, Sumithra J Mandrekar

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Phase I trials are designed to determine the safety, tolerability, and recommended phase 2 dose of therapeutic agents for subsequent testing. The dose-finding paradigm has thus traditionally focused on identifying the maximum tolerable dose of an agent or combination therapy under the assumption that there is a non-decreasing relationship between dose–toxicity and dose–efficacy. The dose is typically determined based on the probability of severe toxicity observed during the first treatment cycle. A novel endpoint, the total toxicity profile, was previously developed to account for the multiple toxicity types and grades experienced in the first cycle. More recently, this was extended to a repeated measures design based on the total toxicity profile to account for longitudinal toxicities over multiple treatment cycles in the absence of within-patient correlation. Methods: In this work, we propose to extend the design in the presence of within-patient correlation. Furthermore, we provide a framework to detect a toxicity time trend (toxicity increasing, decreasing, or stable) over multiple treatment cycles. We utilize a linear mixed model in the Bayesian framework, with the addition of Bayesian risk functions for decision-making in dose assignment. Results: The performance of this design was evaluated using simulation studies and real data from a phase I trial. We demonstrated that using available toxicity data from all cycles of treatment improves the accuracy of maximum tolerated dose identification and allows for the detection of a time trend. The performance is consistent regardless of the strength of the within-patient correlation. In addition, the use of a quasi-continuous total toxicity profile score significantly increased the power to detect time trends compared to when binary data only were used. Conclusion: The increased interest in molecularly targeted agents and immunotherapies in oncology necessitates innovative phase I study designs. Our proposed framework provides a tool to tackle some of the challenges presented by these novel agents, specifically through the ability to understand patterns of toxicity over time, which is important in the cases of cumulative or late toxicities.

Original languageEnglish (US)
Pages (from-to)611-620
Number of pages10
JournalClinical Trials
Volume14
Issue number6
DOIs
StatePublished - Dec 1 2017

Fingerprint

Therapeutics
Aptitude
Maximum Tolerated Dose
Immunotherapy
Linear Models
Decision Making
Safety
Power (Psychology)
Identification (Psychology)

Keywords

  • adaptive
  • continual reassessment method
  • correlated toxicity
  • Dose-finding
  • immunotherapy
  • maximum tolerated dose
  • molecularly targeted agents
  • phase I clinical trials
  • repeated measures
  • time trend

ASJC Scopus subject areas

  • Pharmacology

Cite this

Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. / Yin, Jun; Paoletti, Xavier; Sargent, Daniel J.; Mandrekar, Sumithra J.

In: Clinical Trials, Vol. 14, No. 6, 01.12.2017, p. 611-620.

Research output: Contribution to journalArticle

@article{5386a20fbec64b70b07df277fb4d627f,
title = "Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data",
abstract = "Background: Phase I trials are designed to determine the safety, tolerability, and recommended phase 2 dose of therapeutic agents for subsequent testing. The dose-finding paradigm has thus traditionally focused on identifying the maximum tolerable dose of an agent or combination therapy under the assumption that there is a non-decreasing relationship between dose–toxicity and dose–efficacy. The dose is typically determined based on the probability of severe toxicity observed during the first treatment cycle. A novel endpoint, the total toxicity profile, was previously developed to account for the multiple toxicity types and grades experienced in the first cycle. More recently, this was extended to a repeated measures design based on the total toxicity profile to account for longitudinal toxicities over multiple treatment cycles in the absence of within-patient correlation. Methods: In this work, we propose to extend the design in the presence of within-patient correlation. Furthermore, we provide a framework to detect a toxicity time trend (toxicity increasing, decreasing, or stable) over multiple treatment cycles. We utilize a linear mixed model in the Bayesian framework, with the addition of Bayesian risk functions for decision-making in dose assignment. Results: The performance of this design was evaluated using simulation studies and real data from a phase I trial. We demonstrated that using available toxicity data from all cycles of treatment improves the accuracy of maximum tolerated dose identification and allows for the detection of a time trend. The performance is consistent regardless of the strength of the within-patient correlation. In addition, the use of a quasi-continuous total toxicity profile score significantly increased the power to detect time trends compared to when binary data only were used. Conclusion: The increased interest in molecularly targeted agents and immunotherapies in oncology necessitates innovative phase I study designs. Our proposed framework provides a tool to tackle some of the challenges presented by these novel agents, specifically through the ability to understand patterns of toxicity over time, which is important in the cases of cumulative or late toxicities.",
keywords = "adaptive, continual reassessment method, correlated toxicity, Dose-finding, immunotherapy, maximum tolerated dose, molecularly targeted agents, phase I clinical trials, repeated measures, time trend",
author = "Jun Yin and Xavier Paoletti and Sargent, {Daniel J.} and Mandrekar, {Sumithra J}",
year = "2017",
month = "12",
day = "1",
doi = "10.1177/1740774517723829",
language = "English (US)",
volume = "14",
pages = "611--620",
journal = "Clinical Trials",
issn = "1740-7745",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data

AU - Yin, Jun

AU - Paoletti, Xavier

AU - Sargent, Daniel J.

AU - Mandrekar, Sumithra J

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background: Phase I trials are designed to determine the safety, tolerability, and recommended phase 2 dose of therapeutic agents for subsequent testing. The dose-finding paradigm has thus traditionally focused on identifying the maximum tolerable dose of an agent or combination therapy under the assumption that there is a non-decreasing relationship between dose–toxicity and dose–efficacy. The dose is typically determined based on the probability of severe toxicity observed during the first treatment cycle. A novel endpoint, the total toxicity profile, was previously developed to account for the multiple toxicity types and grades experienced in the first cycle. More recently, this was extended to a repeated measures design based on the total toxicity profile to account for longitudinal toxicities over multiple treatment cycles in the absence of within-patient correlation. Methods: In this work, we propose to extend the design in the presence of within-patient correlation. Furthermore, we provide a framework to detect a toxicity time trend (toxicity increasing, decreasing, or stable) over multiple treatment cycles. We utilize a linear mixed model in the Bayesian framework, with the addition of Bayesian risk functions for decision-making in dose assignment. Results: The performance of this design was evaluated using simulation studies and real data from a phase I trial. We demonstrated that using available toxicity data from all cycles of treatment improves the accuracy of maximum tolerated dose identification and allows for the detection of a time trend. The performance is consistent regardless of the strength of the within-patient correlation. In addition, the use of a quasi-continuous total toxicity profile score significantly increased the power to detect time trends compared to when binary data only were used. Conclusion: The increased interest in molecularly targeted agents and immunotherapies in oncology necessitates innovative phase I study designs. Our proposed framework provides a tool to tackle some of the challenges presented by these novel agents, specifically through the ability to understand patterns of toxicity over time, which is important in the cases of cumulative or late toxicities.

AB - Background: Phase I trials are designed to determine the safety, tolerability, and recommended phase 2 dose of therapeutic agents for subsequent testing. The dose-finding paradigm has thus traditionally focused on identifying the maximum tolerable dose of an agent or combination therapy under the assumption that there is a non-decreasing relationship between dose–toxicity and dose–efficacy. The dose is typically determined based on the probability of severe toxicity observed during the first treatment cycle. A novel endpoint, the total toxicity profile, was previously developed to account for the multiple toxicity types and grades experienced in the first cycle. More recently, this was extended to a repeated measures design based on the total toxicity profile to account for longitudinal toxicities over multiple treatment cycles in the absence of within-patient correlation. Methods: In this work, we propose to extend the design in the presence of within-patient correlation. Furthermore, we provide a framework to detect a toxicity time trend (toxicity increasing, decreasing, or stable) over multiple treatment cycles. We utilize a linear mixed model in the Bayesian framework, with the addition of Bayesian risk functions for decision-making in dose assignment. Results: The performance of this design was evaluated using simulation studies and real data from a phase I trial. We demonstrated that using available toxicity data from all cycles of treatment improves the accuracy of maximum tolerated dose identification and allows for the detection of a time trend. The performance is consistent regardless of the strength of the within-patient correlation. In addition, the use of a quasi-continuous total toxicity profile score significantly increased the power to detect time trends compared to when binary data only were used. Conclusion: The increased interest in molecularly targeted agents and immunotherapies in oncology necessitates innovative phase I study designs. Our proposed framework provides a tool to tackle some of the challenges presented by these novel agents, specifically through the ability to understand patterns of toxicity over time, which is important in the cases of cumulative or late toxicities.

KW - adaptive

KW - continual reassessment method

KW - correlated toxicity

KW - Dose-finding

KW - immunotherapy

KW - maximum tolerated dose

KW - molecularly targeted agents

KW - phase I clinical trials

KW - repeated measures

KW - time trend

UR - http://www.scopus.com/inward/record.url?scp=85037107773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037107773&partnerID=8YFLogxK

U2 - 10.1177/1740774517723829

DO - 10.1177/1740774517723829

M3 - Article

C2 - 28764555

AN - SCOPUS:85037107773

VL - 14

SP - 611

EP - 620

JO - Clinical Trials

JF - Clinical Trials

SN - 1740-7745

IS - 6

ER -